and rightly so if you look at pages 17 and 18 (regarding projections for its likely blockbuster moxduo) of their recent corporate presentation. on virtually all fronts, the MoxDuo combination significantly outperforms oxycodone and morphine (and percocet) and will, IMHO, introduce a new std of pain care once approved.
its CNS drug pipeline is not too shabby either.
the low number of shares circa 75M adds spice.
QRX Price at posting:
66.4¢ Sentiment: Buy Disclosure: Held